193966-43-7

Upstream product

• 2955-88-6 1-pyrrolidineethanol 
• 7368-78-7 4-bromoguaiacol 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 

Downstream Products

• 193966-44-8 6-Benzyloxy-2-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophen-3-yl 3-Methyl-4-[(1-pyrrolidinyl)methyl]phenyl Ketone 
• 942910-32-9 3-cyclohexyloxy-1-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-1H-pyrazin-2-one 
• 942910-41-0 C₁₉H₂₅N₃O₄ 
• 690264-37-0 1-[2-(4-iodo-2-methoxy-phenoxy)-ethyl]-pyrrolidine 
• 215607-03-7 2-[3-Methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-benzo[b]thiophene 

Relevant academic research and scientific papers

NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES

The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-I activity according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereo chemically isomeric form thereof, an TV-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders ; obesity ; diabetes ; sexual disorders and neurological disorders.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.

Antithrombotic agents

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and

Antithrombotic agents

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.